RedHill Biopharma Ltd. (RDHL)
| Market Cap | 2.36M -32.6% |
| Revenue (ttm) | n/a |
| Net Income | -2.40M |
| EPS | n/a |
| Shares Out | 6.08M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 109,144 |
| Open | 0.3995 |
| Previous Close | 0.4166 |
| Day's Range | 0.3801 - 0.4100 |
| 52-Week Range | 0.3801 - 1.6000 |
| Beta | 4.90 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 30, 2026 |
About RDHL
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers’ diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; ... [Read more]
Financial Performance
Financial StatementsNews
$2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma
TEL AVIV, Israel and RALEIGH, N.C., Oct. 19, 2026 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results
Executing a full strategic portfolio reset, RedHill is now a stronger commercial entity with Rebyota® and Clenpiq®, two established FDA-approved gastrointestinal (GI) brands that generated $37.5 milli...
RedHill Biopharma Earnings release: H1 2026
RedHill Biopharma released its H1 2026 earnings on September 30, 2026, summarizing the period's financial results.
RedHill Biopharma Pushes for Growth Securing Rights to Ferring’s $37M Gastrointestinal Drugs Portfolio
RedHill Biopharma ($RDHL) has said the acquisition from Ferring of commercialization rights to two established gastrointestinal (GI) FDA-approved drugs, which together generated around $37.5 million i...
RedHill Sells its Talicia® H. pylori Drug Business to Apotex in $18M Deal to Fuel Growth
RedHill Biopharma ($RDHL) divested its Talicia business to Apotex Health Corp. in an $18 million upfront plus potential milestones deal as part of a strategic roadmap towards transforming its commerci...
RedHill acquires exclusive commercialization rights to Rebyota, Clenpiq for $12M
RedHill Biopharma (RDHL) announced the acquisition of exclusive global and U.S. commercialization rights to Rebyota and Clenpiq, from Ferring Pharmaceuticals, as part of Ferring’s ongoing strategic re...
RedHill announces acquisition of commercialization rights to Rebyota, Clenpiq
RedHill Biopharma (RDHL) announced the transformational acquisition of exclusive global and U.S. commercialization rights to Rebyota and Clenpiq, from Ferring Pharmaceuticals, as part of Ferring’s ong...
RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®
Together with the previously announced Talicia® strategic divestiture, the acquisition from Ferring of commercialization rights to two larger, proprietary, established gastrointestinal (GI) FDA-approv...
Why Is Penny Stock RedHill Biopharma (RDHL) Up 103% Today?
RedHill Biopharma stock rallied over 100% on Monday on news the company will sell its Talicia business for $18 million in cash.
RedHill announces divestment of Talicia business to Apotex Health subsidiary
RedHill Biopharma (RDHL) announced the divestment of its Talicia business to a subsidiary of Apotex Health for an upfront payment of $18M plus up to an additional $35M in potential…
RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities
Executes a major step in RedHill's strategic roadmap to fundamentally reposition the Company's commercial business toward new and larger product opportunities, revenue growth and an accelerated path t...
Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development
The number of confirmed Ebola cases and deaths has increased substantially to 3221 cases and 1407 deaths -- Finalization of development next steps and potential partnership discussions ongoing, includ...
RedHill Biopharma Registration statement: Registration filing
RedHill Biopharma filed a registration statement on July 2, 2026, providing details about a securities offering with the SEC.
RedHill Biopharma Slides: Corporate presentation
RedHill Biopharma has posted slides in relation to its latest quarterly earnings report, which was published on July 1, 2026.
RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement
$6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the exercise in full of warrants TEL AVIV, Israel and RALEIGH, N.C., June 22, 2026 /PRNewswire/ -- ...
RedHill Biopharma announces $19.4M private placement
RedHill Biopharma (RDHL) announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 8,571,429 American Depositary Shares, each ADS representing ten thousand...
RedHill Biopharma Announces Up To $19.4 Million Private Placement
$6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the exercise in full of warrants TEL AVIV, Israel & RALEIGH, N.C., June 18, 2026 /PRNewswire/ -- Re...
RedHill (RDHL) Gains FDA Rare Pediatric Disease Designation, Opening Door to Potential Priority Review Voucher (PRV) Upside
RedHill Biopharma Ltd. ($RDHL) is a specialty biopharmaceutical company focused on developing and commercializing treatments in areas including gastrointestinal diseases, infectious diseases, oncology...
RedHill Biopharma’s Opaganib Ebola Plan Gives RDHL Stock a New Catalyst
RedHill Biopharma Ltd. (NASDAQ:RDHL) is a specialty biopharmaceutical company focused on the U.S. development and commercialization of drugs for gastrointestinal diseases, infectious diseases, and onc...
RedHill Biopharma’s opaganib granted FDA Rare Pediatric Disease designation
RedHill Biopharma (RDHL) announced that the FDA has granted rare pediatric disease, or RPD, designation to opaganib for treatment of neuroblastoma, or NB. The FDA grant of rare pediatric disease…
RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation
The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most commonly affecting babies and young c...
RedHill Biopharma launches enforcement of $11M judgment against Kukbo
RedHill Biopharma (RDHL) announced that it has commenced recognition and enforcement proceedings in Korea in respect of the New York Supreme Court’s final judgment in favor of RedHill against Kukbo…
RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo
RALEIGH, N.C. and TEL-AVIV, Israel, June 8, 2026 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms
Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma is actively d...
Bessor Announces Entering Option for the Redhill Property
Vancouver, BC, May 26, 2026 (GLOBE NEWSWIRE) -- Bessor Minerals Inc. (TSXV:BST) ("Bessor" or the “Corporation”) announces that, on February 9, 2026, it entered into an agreement (the “Agreement”) with...